{"filing":{"accession_number":"0001601485-26-000050","cik":"0001601485","ticker":"ELTX","company_name":"Elicio Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"angn-20260624.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000050/angn-20260624.htm"},"events":[{"id":13488,"run_id":11986,"accession_number":"0001601485-26-000050","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Elicio Therapeutics hosted a virtual key opinion leader event on June 24, 2026, presenting preliminary clinical data on ELI-002 7P in metastatic KRAS-driven pancreatic cancer, including observations of three patients achieving complete responses following ELI-002 7P treatment and subsequent nivolumab-based therapy. This disclosure highlights clinical progress and a planned Phase 1 combination study strategy for a lead product candidate. While the event itself is operational/strategic in nature (a KOL presentation), the underlying clinical data—particularly the 100% complete response rate in three patients and the hypothesis-generating findings supporting further development—would materially affect a reasonable investor's assessment of the company's pipeline and product potential. The disclosure is material because it provides significant clinical validation for a key development program, though it is not a formal earnings release, M\u0026A activity, or other specifically-named event type.","company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10631,"accession_number":"0001601485-26-000050","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Elicio Therapeutics hosted a virtual key opinion leader event on June 24, 2026, presenting preliminary clinical data on ELI-002 7P in metastatic KRAS-driven pancreatic cancer, including observations of three patients achieving complete responses following ELI-002 7P treatment and subsequent nivolumab-based therapy. This disclosure highlights clinical progress and a planned Phase 1 combination study strategy for a lead product candidate. While the event itself is operational/strategic in nature (a KOL presentation), the underlying clinical data—particularly the 100% complete response rate in three patients and the hypothesis-generating findings supporting further development—would materially affect a reasonable investor's assessment of the company's pipeline and product potential. The disclosure is material because it provides significant clinical validation for a key development program, though it is not a formal earnings release, M\u0026A activity, or other specifically-named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:07:56.690283+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10631,"accession_number":"0001601485-26-000050","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Elicio Therapeutics hosted a virtual key opinion leader event on June 24, 2026, presenting preliminary clinical data on ELI-002 7P in metastatic KRAS-driven pancreatic cancer, including observations of three patients achieving complete responses following ELI-002 7P treatment and subsequent nivolumab-based therapy. This disclosure highlights clinical progress and a planned Phase 1 combination study strategy for a lead product candidate. While the event itself is operational/strategic in nature (a KOL presentation), the underlying clinical data—particularly the 100% complete response rate in three patients and the hypothesis-generating findings supporting further development—would materially affect a reasonable investor's assessment of the company's pipeline and product potential. The disclosure is material because it provides significant clinical validation for a key development program, though it is not a formal earnings release, M\u0026A activity, or other specifically-named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:07:56.690283+00:00","company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","filing_date":"2026-06-24"}]}